Activity of tigecycline in the treatment of acute Burkholderia pseudomallei infection in a murine model.
Burkholderia pseudomallei is the causative agent of melioidosis. Standard therapy includes ceftazidime alone or in combination with co-trimoxazole. Tigecycline, a novel agent, has displayed activity against B. pseudomallei. We evaluated the in vivo efficacy of tigecycline using a murine model of melioidosis. Mice were infected with either a high or low virulence B. pseudomallei isolate followed by administration of antibiotics alone or in combination (tigecycline, ceftazidime, tigecycline plus ceftazidime) for 7 days. Bacterial loads were assessed up to 7 days and survival was determined up to 7 days post infection. Tigecycline in combination with ceftazidime was the most effective and conferred the lowest mortality, suggesting the use of this new agent in B. pseudomallei infection.
Feterl
Marshall
M
School of Veterinary and Biomedical Sciences, James Cook University, Townsville, Qld 4811, Australia.
Govan
Brenda
B
Engler
Cathy
C
Norton
Robert
R
Ketheesan
Natkunam
N
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use; D016957:Burkholderia pseudomallei / Q000187:drug effects* / Q000302:isolation & purification / Q000472:pathogenicity; D002442:Ceftazidime / Q000494:pharmacology / Q000627:therapeutic use; D004195:Disease Models, Animal; D004359:Drug Therapy, Combination; D006801:Humans; D008554:Melioidosis / Q000188:drug therapy* / Q000382:microbiology / Q000401:mortality; D051379:Mice; D008807:Mice, Inbred BALB C; D008826:Microbial Sensitivity Tests; D008911:Minocycline / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D013154:Spleen / Q000382:microbiology; D015996:Survival Rate; D000078304:Tigecycline; D014774:Virulence
D000900:Anti-Bacterial Agents; D000078304:Tigecycline; D002442:Ceftazidime; D008911:Minocycline